Alto Neuroscience, Inc. (ANRO)
Largest Insider Buys in Sector
ANRO Stock Price History Chart
ANRO Stock Performance
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It …
Insider Activity of Alto Neuroscience, Inc.
Over the last 12 months, insiders at Alto Neuroscience, Inc. have bought $190,833 and sold $0 worth of Alto Neuroscience, Inc. stock.
On average, over the past 5 years, insiders at Alto Neuroscience, Inc. have bought $190,833 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Savitz Adam (CHIEF MEDICAL OFFICER) — $190,833.
The last purchase of 2,931 shares for transaction amount of $38,748 was made by Savitz Adam (CHIEF MEDICAL OFFICER) on 2024‑07‑10.
List of Insider Buy and Sell Transactions, Alto Neuroscience, Inc.
| 2024-07-10 | CHIEF MEDICAL OFFICER | 2,931 0.0326% | $13.22 | $38,748 | -16.93% | |||
| 2024-07-09 | CHIEF MEDICAL OFFICER | 12,069 0.1279% | $12.60 | $152,085 | -19.73% |